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mediated metabolic tumor effects using in vivo achievable 
biguanide concentrations. 
Materials and Methods: Initially we developed 11C labeled 
MET, which allowed assessment of in vitro cellular drug 
uptake and, importantly, in vivo biodistribution assessment 
using PET scans or organ dissection in tumor-bearing mice. 
Based on those results cellular effects of physiologically 
relevant doses of biguanides were tested in 14 cell lines using 
assays of proliferation/viability, glucose metabolism (FDG 
retention), respiration and lactic acid production 
(extracellular flux analyzer) and stress signaling. 
Finally, the two tumor models SiHa (cervix) and A549 (lung) 
were established in mice to assess acute and long-term 
metabolic, microenvironmental and anti-proliferative effects 
of PHEN treatment. 
Results: In vivo results showed that [MET] in blood peaked at 
250 μM in mice administered maximum tolerable dose (250 
mg/kg). Furthermore, MET was retained by tumor cells in 
vitro as well as in vivo, and uptake could be blocked by 
unlabeled MET suggesting involvement of OCTs. MET uptake 
varied widely among cell lines, with the highest uptake in 
A549. Likewise, inhibition of respiration and stimulation of 
glucose use and cell viability/proliferation was mostly 
affected in cell lines with high MET uptake. Even so, most 
cell lines were insensitive to in vivo achievable MET 
concentrations. PHEN was 100 times more potent than MET 
and induced profound metabolic changes at 50 μM in all cell 
lines, and down to a physiological relevant concentration of 1 
μM in A549. In accordance, PHEN was chosen for further 
testing in tumor-bearing mice. Data analysis of tumor 
microenvironment (hypoxia) and growth is ongoing.  
Conclusions: Biguanides affect cellular energy metabolism 
and proliferation in vitro but metabolic effects of MET were 
typically restricted to non-physiological concentrations and 
MET retention and sensitivity varied significantly among cell 
lines. PHEN exerted similar effects as MET but with greater 
potency and may affect a broader selection of tumors at 
physiologically achievable concentrations. Labeling of 
biguanides may allow PET-based identification of patients 
with treatment-responsive tumors. 
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Purpose/Objective: Carbon ions (12C-ions) show an increased 
relative biological effectiveness (RBE) relative to photons. To 
compare the impact of intra- and intertumor heterogeneity 
on the RBE, dose-response curves for photons and 12C-ions 
were determined for three sublines of a syngeneic rat 
prostate adenocarcinoma. 
Materials and Methods: Fresh tumor fragments from three 
sublines (AT1, HI and H) of the Dunning prostate tumor R3327 
were transplanted subcutaneously into the distal right thigh 
of male Copenhagen rats. Tumors were treated once with 
increasing single doses of either 12C-ions or 6 MeV photons. 
Primary endpoint was local tumor control within 300 days. 
For the H-tumor, histological tumor control, defined as 
absence of proliferation (BrdU-injection) in the remaining 
fibrotic nodules (Hematoxylin/Eosin staining) was used as 
secondary endpoint. RBE-values were calculated by the ratio 
of TCD50-values (dose to achieve 50% tumor control 
probability) for photons and 12C-ions, respectively. 
Results: Local tumor control can be achieved with 12C-ions 
and photons in all three sublines. For all tumors an increased 
effectiveness of 12C-ions was observed. The RBE for local 
tumor control increased from 1.62 ± 0.11 (H) to 2.08 ± 0.13 
(HI) to 2.30 ± 0.08 (AT1). Using histological tumor control, 
the RBE for the H-tumor increased to 1.80 ± 0.13. For 12C-ion 
irradiations the variation of TCD50-values between tumor 
sublines was significantly smaller than after photon 
irradiation. Additionally 12C-ion dose-response curves were 
much steeper compared to photons indicating a smaller 
intratumor heterogeneity for 12C-ions. 
Conclusions: The study confirms the increased relative 
biological effectiveness of 12C-ions in tumors, which is the 
highest for the highly radioresistant AT1-tumor and the 
smallest for the well-differentiated H-tumor. The very 
heterogeneous moderately differentiated HI-tumor lies in 
between. This indicates a clear correlation between 
decreasing differentiation status and increasing RBE. 12C-ions 
may therefore be beneficial especially in undifferentiated 
tumors, with a high photon resistance. Changes of RBE with 
tumor differentiation were predominantly caused by changes 
in the photon response. This supports the assumption that 
the response to 12C-ions is less dependent on tumor 
heterogeneity compared to photons. Thus heterogeneities 
within patient populations or the existence of radioresistant 
subpopulations within single tumors may be expected to have 
less impact on the 12C-ions radiation response. The underlying 
differential mechanisms are currently analyzed in ongoing 
histological and functional experiments.  
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Purpose/Objective: For several years evidence is 
accumulating that not only the more eminent known nuclear 
DNA mutations but also different variations (e.g. deletions 
and mutations) in the mitochondrial DNA (mtDNA) are 
associated with a wide variety of cancers. Unlike nuclear DNA 
(nDNA), mtDNA is polyploid, only maternally inherited and is 
encoding for 13 subunits of the oxidative phosphorylation 
(OXPHOS) machinery responsible for aerobic ATP production. 
Several mutations and variations in genes involved in OXPHOS 
are associated with a decreased ATP production and 
increased oxidative stress. Current study aimed at 
characterizing proliferation, metabolism and intrinsic 
radiosensitivity in ρ0 cells, cell lines depleted from their 
mtDNA. We hypothesized that ρ0 cells have a pronounced 
glycolytic profile resulting in radiosensitization compared to 
their parental counterparts. 
Materials and Methods: ρ0 cells were generated by depleting 
BEAS-2B (lung/bronchus epithelial) immortalized cells or 
A549 (lung adenocarcinoma) and 143B (osteosarcoma) tumor 
cell lines from their mtDNA by adding ethidium bromide (50 
ng/ml) to the culture media for several weeks. mtDNA copy 
number was checked by qPCR. Proliferation was assessed 
using the IncuCyte FLR and metabolic profiles (mitochondrial 
and glycolysis stress test) were generated using the Seahorse 
XF96. Radiosensitivity was investigated by performing 
clonogenic survival assays after exposing cells to different 
irradiation doses. 
Results: For the parental cell lines, the A549 cells had a 
higher mitochondrial ATP production, less spare OXPHOS 
capacity and more proton leak. 143B were more dependent 
on glucose metabolism and had the lowest glycolytic reserve 
capacity. The BEAS-2B cells showed an intermediate result 
for both assays. Different characteristics of a ρ0 cell are 
changed compared to its parental cell. All ρ0 cell lines 
showed reduced mitochondrial respiration, whereas 
increased glycolysis was observed with a lack of glycolytic 
reserve compared to the parental lines. The ρ0 phenotype 
also resulted in a decreased proliferative capacity of these 
cells. Dose response curves showed that BEAS-2B ρ0 cells 
were more radioresistant (p<0.0001) while 143B ρ0 showed a 
more radiosensitive phenotype compared to the parental 
counterparts (p<0.0007). For the A549 cells no differences 
were found for radiosensitivity between parental and ρ0 cell 
lines. 
Conclusions: These findings suggest that different types of ρ0 
react differently upon irradiation. It has been suggested that 
the capacity to cope with metabolic stress determines the 
radiosensitivity of tumor cells and might be correlated to the 
metabolic profile of the parental cells. Therefore, we are 
currently investigating if varying ROS levels or basal ATP 
production of the cells drives these differences in 
radiosensitivity by e.g. influencing antioxidant defenses and 
if known OXPHOS inhibitors (e.g. rotenone, metformin) could 
potentially demonstrate the same effects.  
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Purpose/Objective: Respiration-induced tumor motion is an 
important source of geometric uncertainty in radiotherapy 
for (gastro-) esophageal cancer. However, it is difficult to 
quantify this motion particularly in the cranio-caudal (CC) 
direction due to the limited soft tissue contrast on CT. In this 
study, we aimed at quantifying esophageal tumor motion 
relative to the bony anatomy using markers and 4DCT data.  
Materials and Methods: Eighteen esophageal cancer patients 
underwent endoscopy-guided implantation of in total 65 
markers, of 3 different types, at the cranial border, caudal 
border, and/or the center of the primary tumor. A 4DCT scan 
was acquired after marker implantation for all patients. 
Table 1 gives an overview of patient and marker 
characteristics. The 4DCT scans were reconstructed and 
sorted into 10 phases throughout a breathing cycle. 
Retrospectively, for each patient, the 1st phase (0%, the end 
of inhale) in the 4DCT was selected as the reference to which 
the 9 remaining phases were rigidly registered based on the 
vertebra. Then, markers were manually identified and 
classified into 3 groups based on their positions in the 
esophagus as measured from the incisors: proximal, mid and 
distal esophagus. Next, individual marker displacements in 
each phase relative to the reference positions were assessed 
in the left-right (LR), CC, anterior-posterior (AP) directions, 
and vector distance (3D). 
Results: In total, 56 markers could be identified: 3, 13 and 40 
markers in the proximal, mid, and distal esophagus, 
respectively (Table 1, Figure 1). Different types of markers 
showed no difference in visibility on 4DCT. Figure 1 shows the 
mean and standard deviation (SD) of the marker 
displacements relative to the reference in each breathing 
phase. Also the distribution of the maximum difference in 
marker position over the course of one breathing cycle in the 
LR, CC, and AP directions as well as in 3D is shown. For all 56 
markers, the maximum difference in position (mean ± SD) 
was 3.0 ± 2.1, 6.0 ± 2.8, and 3.4 ± 2.0 mm in the LR, CC, and 
AP directions, respectively. Overall, displacements were 
significantly larger in the CC than in the LR and AP directions 
(p<0.05, Wilcoxon signed-rank test). However, for all 4 
distally located markers in patient 13 distinct larger 
displacements in the LR than in the CC and AP directions 
were observed. Moreover, the 3D maximum difference in 
marker position was 2.9 ± 1.1 in the proximal, 3.6 ± 1.8 in 
the mid, and 8.6 ± 2.4 mm in the distal esophagus. In all 3 
directions and in 3D, displacements of markers located in the 
distal esophagus were significantly larger than of markers in 
the proximal and mid esophagus (p<0.05, Wilcoxon rank-sum 
test).
Conclusions: Generally, respiration-induced motion is largest 
in the CC direction. However, the motion in the LR and 
AP directions cannot be neglected when the tumor is 
located in the distal esophagus. Hence, with clearly visible 
markers on 4DCT, the respiration-induced motion could be 
incorporated to individualize the safety margin, by for 
instance using an internal target volume, mid-ventilation, 
or breath-control technique.  
